Stocks · News reference

HC Wainwright & Co. Maintains Buy Rating on Celcuity, Lowers Price Target

2026-11-09 12:32:31 UTC

HC Wainwright & Co. has reaffirmed its 'Buy' rating on Celcuity Inc. while adjusting the price target to $150 from $155.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.ai2026-11-09 19:03:43 UTC
Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib)
The FDA has accepted Celcuity's supplemental New Drug Application (sNDA) for REVTORPYK™ (gedatolisib) to treat HR+/HER2-, PIK3CA-mutant locally advanced or metastatic breast cancer.
CELC
Benzinga2026-11-09 13:34:35 UTCBenzinga Newsdesk
Celcuity's Supplemental New Drug Application For REVTORPYK Accepted for FDA Review To Treat Hormone Receptor Positive
CELC
Benzinga2026-11-09 13:19:07 UTCAvi Kapoor
Block To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Monday
Analysts raised targets for Magnite, Airbnb and Choice Hotels; cut targets for Unusual Machines, DraftKings, PDD and TeraWulf. DKNG and PDD downgraded.
ABNB CELC CHH DKNG MGNI
Benzinga2026-11-09 11:23:53 UTCBenzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Celcuity, Lowers Price Target to $150
CELC
Benzinga2026-11-06 16:01:07 UTCBenzinga Newsdesk
Guggenheim Maintains Buy on Celcuity, Lowers Price Target to $169
CELC
Fiscal.ai2026-11-05 23:02:21 UTC
Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Celcuity Inc. announced its financial results for the third quarter ended September 30, 2026, alongside updates on the commercial launch of REVTORPYK™ and ongoing clinical trial progress.
CELC